ClinicalTrials.gg
CompletedNCT06418620Updated May 17, 2024

A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants

A Phase 1 interventional study of Venglustat in Healthy Volunteers, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2020, 6 years 3 months ago, and no results have been posted to the registry.
  • Registered 3 years 10 months after the study started (first participant enrolled Jun 2020, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effect of food on the bioavailability of venglustat and to assess the relative bioavailability of venglustat tablet swallowed whole with water versus a tablet chewed and then swallowed without water. Also, to evaluate the safety and tolerability of a single dose tablet of venglustat under fed (swallowed whole) and fasted (swallowed whole or chewed) conditions in healthy adult participants. The maximum duration for participants from screening is up to 63 days.

Read the detailed description

Total study duration for participants is up to 63 days including screening up to 27 days, 1 day of treatment in period 1 of 7 days, washout of 3 days, 1 day of treatment in period 2 of 7 days, washout of 3 days, 1 day of treatment in period 3 of 7 days, followed by a final observation over 7 days (+/- 2 days).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: -Male and/or female participant, between 18 and 45 years of age, inclusive.

  • between 18.0 and 30.0 kg/m2, inclusive.
  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
  • Vital signs after 10 minutes resting in supine position within the following ranges:
  • 95 mmHg \< systolic blood pressure (SBP) \<140 mmHg
  • 50 mmHg \< diastolic blood pressure (DBP) \<90 mmHg
  • 50 bpm \< heart rate (HR) \<100 bpm
  • Standard 12-lead (ECG) parameters after 10 minutes resting in supine position in the following ranges; 120 ms \< PR \<220 ms, QRS \<120 ms, ≤450 ms (Fridericia algorithm recommended), 50 bpm \< HR \<100 bpm and normal ECG tracing unless the Investigator considers an ECG tracing abnormality to be not .
  • Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for healthy participant.
  • Having given written prior to undertaking any study-related procedure.
  • Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
  • Not under any administrative or legal supervision or under institutionalization due to regulatory or juridical order.
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Men or women of (WOCBP as defined by the protocol) are required to either practice true abstinence consistent with their preferred and usual lifestyle, or use double contraceptive methods for the entire duration of the treatment until 6 weeks after the last treatment with venglustat for women and until 90 days for men. "Double-contraceptive methods" means:
  • A barrier method such as a condom or occlusive cap (diaphragm or cervical/vault cap) with spermicidal foam/gel/film/cream/suppository, and,
  • An established non-barrier method, such as oral, injected, or implanted hormonal methods, an intrauterine device, or an intrauterine system.
  • In addition, male participants must refrain from donating sperm from the inclusion up to 3 months after the last dosing.
  • Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of penile penetration from the inclusion up to 3 months after the last dosing. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
  • Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
  • Blood donation, any volume, within 2 months before inclusion.
  • Presence or history of clinically significant drug , or allergic disease diagnosed and treated by a physician.
  • History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis). Note that 12 fluid ounces of regular beer, 5 fluid ounces of wine, and 1.5 fluid ounces of distilled spirits each contain approximately 14 g of alcohol.
  • Smoking regularly more than approximately 5 cigarettes or equivalent per week, unable to stop smoking during the study (occasional smoker can be enrolled). Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day).
  • If female, pregnancy (defined as positive β-HCG test) or breast-feeding.
  • Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion. Any drug which could impact by any mechanism of action, the pharmacokinetics of the medicinal product, including moderate and strong inhibitors or inducers.
  • Any participant who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
  • Any participant enrolled or having participated, in any other clinical study involving an investigational medicinal product or in any other type of medical research, and is still in the exclusion period according to applicable regulations.
  • Any participant who cannot be contacted in case of emergency.
  • Any participant who is the Investigator or any subinvestigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study, or any person dependent (employees or immediate family members) on the study site, the Investigator or the Sponsor.
  • Prisoners or participant who are legally institutionalized.
  • Positive result on any of the following tests: surface (HBs Ag) antigen, anti virus (anti-HCV) antibodies, anti- 1 and 2 antibodies (anti-HIV-1 and anti HIV-2 Ab).
  • Positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
  • Positive alcohol test.
  • Any consumption of citrus fruits (grapefruit, orange, etc) or their juices within 5 days before inclusion.
  • Any participant who cannot comply with the following study restrictions: refraining from drinking alcohol, tea, coffee, chocolate, quinine, or caffeine-containing beverages from 1 day before institutionalization and throughout the study duration; not smoking or using tobacco from 1 day prior to institutionalization throughout the study duration until the end-of-study visit; following a stable lifestyle with no intensive physical activity from 1 day prior to institutionalization throughout the study duration until the end-of-study visit.
  • Lack of sufficiently healthy dentition for chewing a hard tablet.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Treatment A

    Fasted, venglustat tablet swallowed with water

    Drug: Venglustat

  • Experimental
    Treatment B

    Fasted, venglustat tablet chewed and swallowed without water

    Drug: Venglustat

  • Experimental
    Treatment C

    Fed, venglustat tablet swallowed with water

    Drug: Venglustat

Interventions

  • Pharmaceutical form:Tablet-Route of administration:Oral

    Also known as: GZ/SAR402671

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration observed (Cmax) of venglustat

    Time frame: Multiple time points up to day 27

  2. Area under the plasma concentration versus time curve calculated from time zero to the real time (tlast) (AUClast) of venglustat

    Time frame: Multiple time points up to day 27

  3. Area under the plasma concentration versus time curve (AUC) of venglustat

    Time frame: Multiple time points up to day 27

Secondary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: Multiple time points up to day 63

  2. Time to reach Cmax (tmax) of venglustat

    Time frame: Multiple time points up to day 27

  3. Interval between administration time and the sampling time preceding the first concentration above the limit of quantification (tlag) of venglustat

    Time frame: Multiple time points up to day 27

  4. Terminal half-life associated with the terminal slope (λz) (t1/2z) of venglustat

    Time frame: Multiple time points up to day 27

  5. Apparent total body clearance of a drug from the plasma (CL/F) of venglustat

    Time frame: Multiple time points up to day 27

  6. Apparent volume of distribution at steady state (Vss/F) of venglustat

    Time frame: Multiple time points up to day 27

07

Study locations

1 site
  • Prism Research Site Number : 8400001
    Saint Paul, Minnesota 55114, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Aug 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2024
First posted
May 17, 2024
StartActual
Jun 18, 2020
Primary completionActual
Aug 7, 2020
CompletionActual
Aug 7, 2020
Last update
May 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06418620
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 17, 2024
Start date
Jun 18, 2020
Primary completion
Aug 7, 2020
Completion
Aug 7, 2020
Last update
May 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venglustat

Start the discussion